MXPA05009007A - Medicamento que comprende un agonista beta2 de accion prolongada altamente potente en combinacion con otros ingredientes activos. - Google Patents

Medicamento que comprende un agonista beta2 de accion prolongada altamente potente en combinacion con otros ingredientes activos.

Info

Publication number
MXPA05009007A
MXPA05009007A MXPA05009007A MXPA05009007A MXPA05009007A MX PA05009007 A MXPA05009007 A MX PA05009007A MX PA05009007 A MXPA05009007 A MX PA05009007A MX PA05009007 A MXPA05009007 A MX PA05009007A MX PA05009007 A MXPA05009007 A MX PA05009007A
Authority
MX
Mexico
Prior art keywords
active ingredients
combination
agonist
beta2
lasting
Prior art date
Application number
MXPA05009007A
Other languages
English (en)
Inventor
Pastore Fiorella
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05009007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MXPA05009007A publication Critical patent/MXPA05009007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere al uso de un broncodilatador en combinacion con uno o mas ingredientes activos adicionales para el tratamiento de trastornos respiratorios y especialmente asma y enfermedades pulmonares obstructivas cronicas (por sus siglas en ingles, COPD), y a composiciones farmaceuticas que contienen dichos ingredientes activos. En particular, la invencion se refiere al uso de agonistas (2 de accion prolongada de 8-hidroxi -5-[ (1R)- 1-hidroxi- 2-[[(1R)- 2-(4 -metoxifenil)- 1-metiletil] amino] etil] -2 (1H)- quinolinona y/o sales y/o solvatos de los mismos fisiologicamente aceptables como un broncodilatador en combinacion con otros ingredientes activos.
MXPA05009007A 2003-02-27 2004-02-27 Medicamento que comprende un agonista beta2 de accion prolongada altamente potente en combinacion con otros ingredientes activos. MXPA05009007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (en) 2003-02-27 2003-02-27 Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
PCT/EP2004/001960 WO2004075896A1 (en) 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Publications (1)

Publication Number Publication Date
MXPA05009007A true MXPA05009007A (es) 2005-10-18

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009007A MXPA05009007A (es) 2003-02-27 2004-02-27 Medicamento que comprende un agonista beta2 de accion prolongada altamente potente en combinacion con otros ingredientes activos.

Country Status (32)

Country Link
US (1) US20070020190A1 (es)
EP (3) EP1452179A1 (es)
JP (1) JP2006519204A (es)
KR (1) KR20050104367A (es)
CN (2) CN101244063A (es)
AR (1) AR043419A1 (es)
AT (1) ATE401887T1 (es)
AU (1) AU2004216472B2 (es)
BR (1) BRPI0408047A (es)
CA (1) CA2517321A1 (es)
CY (1) CY1108360T1 (es)
DE (1) DE602004015260D1 (es)
DK (1) DK1603565T3 (es)
EA (1) EA008828B1 (es)
ES (1) ES2309503T3 (es)
HK (1) HK1087009A1 (es)
HR (1) HRP20050726A2 (es)
MA (1) MA27630A1 (es)
ME (1) MEP32208A (es)
MX (1) MXPA05009007A (es)
NO (1) NO20053959L (es)
NZ (1) NZ541997A (es)
PE (1) PE20050290A1 (es)
PL (1) PL377814A1 (es)
PT (1) PT1603565E (es)
RS (1) RS20050615A (es)
SA (1) SA04250122B1 (es)
SI (1) SI1603565T1 (es)
TN (1) TNSN05186A1 (es)
UA (1) UA82217C2 (es)
WO (1) WO2004075896A1 (es)
ZA (1) ZA200506820B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EP1654001A2 (en) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising steroids and a betamimetic
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
ES2332290T3 (es) * 2005-08-01 2010-02-01 Chiesi Farmaceutici S.P.A. Formulaciones farmaceuticas que comprenden un agonista de beta2 de accion prolongada para su administracion mediante nebulizacion.
WO2007058971A2 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
JP5107933B2 (ja) * 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
CA2650813A1 (en) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh New long-acting drug combinations for the treatment of respiratory diseases
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
WO2009079078A1 (en) 2007-12-14 2009-06-25 Labogroup S.A.S. Delivering aerosolizable food products
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
EP2435081B1 (en) * 2009-05-25 2013-04-17 Chiesi Farmaceutici S.p.A. A therapeutic combination comprising a pulmonary surfactant and a steroid
TWI695723B (zh) 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2011136753A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
WO2012010854A1 (en) 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
PT2968312T (pt) * 2013-03-15 2018-04-19 Verona Pharma Plc Combinação de fármacos
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
US11026918B2 (en) 2014-11-24 2021-06-08 The Board Of Trustees Of The University Of Illinois Method of preventing or treating a pulmonary disease or condition
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CN1149076C (zh) * 1997-03-20 2004-05-12 先灵公司 粉末附聚物的制备方法
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
ATE465712T1 (de) * 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
BRPI0408047A (pt) 2006-02-14
EP1603565B1 (en) 2008-07-23
PT1603565E (pt) 2008-10-06
ES2309503T3 (es) 2008-12-16
CN101244063A (zh) 2008-08-20
KR20050104367A (ko) 2005-11-02
MEP32208A (en) 2010-10-10
EP1834643A2 (en) 2007-09-19
HK1087009A1 (en) 2006-10-06
WO2004075896A1 (en) 2004-09-10
NZ541997A (en) 2008-12-24
AU2004216472A1 (en) 2004-09-10
RS20050615A (en) 2007-09-21
NO20053959D0 (no) 2005-08-25
DE602004015260D1 (de) 2008-09-04
UA82217C2 (uk) 2008-03-25
US20070020190A1 (en) 2007-01-25
EP1452179A1 (en) 2004-09-01
PL377814A1 (pl) 2006-02-20
AU2004216472B2 (en) 2009-08-06
PE20050290A1 (es) 2005-05-26
JP2006519204A (ja) 2006-08-24
CA2517321A1 (en) 2004-09-10
EA008828B1 (ru) 2007-08-31
HRP20050726A2 (en) 2006-02-28
DK1603565T3 (da) 2008-11-10
CN100370986C (zh) 2008-02-27
SA04250122B1 (ar) 2009-03-11
NO20053959L (no) 2005-11-28
ZA200506820B (en) 2006-11-29
MA27630A1 (fr) 2005-11-01
EP1834643A3 (en) 2007-10-24
AR043419A1 (es) 2005-07-27
TNSN05186A1 (en) 2007-06-11
CN1753678A (zh) 2006-03-29
EA200501108A1 (ru) 2006-04-28
SI1603565T1 (sl) 2008-10-31
EP1603565A1 (en) 2005-12-14
CY1108360T1 (el) 2014-02-12
ATE401887T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
TNSN05186A1 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
CA2389349A1 (en) Aerosol composition comprising formoterol
CA2395653A1 (en) New inhalable powder containing tiotropium
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
RS76604A (en) Pressuriesed metered dose inhalers containing solutions of beta-2 agonists
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2004104018A3 (en) Compositions for delivering peptide yy and pyy agonists
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
CA2519679A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
IL168704A (en) Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis
MX2018014425A (es) Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
EP2315589A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
EA200601531A1 (ru) Моногидрохлорид 8-гидрокси-5-[(1r)-1-гидрокси-2-[[(1r)-2-(4-метоксифенил)-1-метилэтил]амино]этил]-2(1h)-хинолинона в кристаллической форме и способ его получения
WO2003039439A3 (de) Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
TW200500066A (en) New tiotropium containing powder formulation for inhalation

Legal Events

Date Code Title Description
FG Grant or registration